Sign in

CIK 0002124080 · <br>Emerging growth company

Aspen Neuroscience, Inc.

Sign in to watch
Ticker
ASPE
Exchange
Nasdaq
Industry
Pharmaceutical Preparations
FY end
Dec 31
Incorporated
DE
Entity type
other
EIN
831312969
Phone
858.263.1222
Business address
10835 ROAD TO THE CURE, SUITE 100, SAN DIEGO, CA, 92121
Open-market buys, last 90 days
$67,999,995
in 4 filings
Open-market sales, last 90 days
$0
in 0 filings

Net +$67,999,995. Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.

Pace of trading Bought Sold

Who's trading

90 days

  1. ARCH Venture Fund X, L.P. +$20.0M 10% owner 1 filing
  2. ARCH Venture Partners XIV, L.P. +$18.0M 10% owner 1 filing
  3. ORBIMED ADVISORS LLC +$15.0M Director 1 filing
  4. Thompson Peter A. +$15.0M Director 1 filing
Date Insider Transaction Shares Price Value Owned after
2026-11-02 ARCH Venture Fund X, L.P. 10% owner Conversion · Series B Convertible Preferred Stock −295,490 0
2026-11-02 ARCH Venture Fund X, L.P. 10% owner Conversion · Series B Convertible Preferred Stock −295,490 0
2026-11-02 ARCH Venture Fund X, L.P. 10% owner Conversion · Series C Convertible Preferred Stock −259,948 0
2026-11-02 ARCH Venture Fund X, L.P. 10% owner Conversion · Series C Convertible Preferred Stock −214,355 0
2026-11-02 ARCH Venture Partners XIV, L.P. 10% owner Purchase +1,200,000 $15.00 $18.0M 1,200,000
2026-11-02 Spaventa Andrew Director Conversion +70,194 70,194
2026-11-02 Spaventa Andrew Director Conversion +180,221 180,221
2026-11-02 Spaventa Andrew Director Conversion · Series Seed Convertible Preferred Stock −70,194 0
2026-11-02 Spaventa Andrew Director Conversion · Series C Convertible Preferred Stock −180,221 0
2026-11-02 Hasnain Faheem Executive Chair Conversion +14,913 14,913
2026-11-02 Hasnain Faheem Executive Chair Conversion +14,316 14,316
2026-11-02 Hasnain Faheem Executive Chair Conversion +7,120 7,120
2026-11-02 Hasnain Faheem Executive Chair Conversion · Series A-1 Convertible Preferred Stock −14,913 0
2026-11-02 Hasnain Faheem Executive Chair Conversion · Series A-2 Convertible Preferred Stock −14,316 0
2026-11-02 Hasnain Faheem Executive Chair Conversion · Series C Convertible Preferred Stock −7,120 0

Page 3 of 3 · 55 trades